KIORA PHARMACEUTICALS INC
Close on Oct 19, 2026
- Market cap
- $14.70M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 6, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 7, 2026 | Before market open | – | $-0.34 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 8, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 25, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 7, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 8, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 9, 2025 | Before market open | – | $-0.52 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 25, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 8, 2024 | Before market open | – | $-0.81 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 9, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 10, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 25, 2024 | Before market open | – | – | – |
Press releases
Announcements Kiora Pharmaceuticals filed with the SEC
Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
Regulation FD disclosure · EX-99.1 to Form 8-K
Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million led by Perceptive Advisors
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Kiora Pharmaceuticals Announces Management Team Changes
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials
Results of operations · EX-99.1 to Form 8-K
Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases
Results of operations · EX-99.1 to Form 8-K
Kiora Pharmaceuticals, Inc. NASDAQ: KPRX 13 Aug 2025 | Corporate Overview H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases
Results of operations · EX-99.1 to Form 8-K
Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies
Results of operations · EX-99.1 to Form 8-K
Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa
Regulation FD disclosure · EX-99.1 to Form 8-K
Kiora Pharmaceuticals, Inc. NASDAQ: KPRX Q4 2024 | Corporate Overview
Regulation FD disclosure · EX-99.2 to Form 8-K
Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies
Results of operations · EX-99.1 to Form 8-K
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease
Results of operations · EX-99.1 to Form 8-K
Kiora Pharmaceuticals, Inc. NASDAQ: KPRX H1 2024 | Corporate Overview
Regulation FD disclosure · EX-99.1 to Form 8-K
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
removed, KIO-301 reverts to its lower energy shape, stopping the signaling to the brain. In this way, the molecule acts as a light switch within the eye.
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Kiora Pharmaceuticals, Inc. NASDAQ: KPRX Strategic Collaboration with Théa | January 31, 2024
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Kiora Pharmaceu-cals, Inc. NASDAQ: KPRX Q4 2023 | Corporate Overview
Regulation FD disclosure · EX-99.1 to Form 8-K
Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years
Executive or director change · Other events · EX-99.1 to Form 8-K
Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27
Other events · EX-99.1 to Form 8-K
Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress
Results of operations · EX-99.1 to Form 8-K
Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
Material agreement · Other events · EX-99.1 to Form 8-K
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
Material agreement · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Kiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
Material agreement · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K
Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments
Results of operations · EX-99.1 to Form 8-K
Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are Blind
Other events · EX-99.1 to Form 8-K
Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress
Results of operations · EX-99.1 to Form 8-K
Kiora Pharmaceuticals Receives Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases
Other events · EX-99.1 to Form 8-K
Kiora Pharmaceuticals Enters Into Two Equity Purchase Agreements with Lincoln Park Capital
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K